23 results found.

Severe Thrombocytopenia Clinical Trial using oprelvekin

Pfizer - Recruiting 18 years to 65 years.
- Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy.
oprelvekin

Myelodysplastic Syndrome Clinical Trial using Oral Azacitidine; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Oral Azacitidine; Placebo

Myelodysplastic Syndromes, or Thrombocytopenia Clinical Trial using Eltrombopag

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS).
Eltrombopag

Aplastic Anemia, Neutropenia, Pancytopenia, Anemia, or Thrombocyt Clinical Trial using Eltrombopag; Horse Anti-Thymocyte Globulin (ATG); Cyclosporine A (CSA)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia.
Eltrombopag; Horse Anti-Thymocyte Globulin (ATG); Cyclosporine A (CSA)

Fanconi's Anemia, Anemia, Diamond Blackfan, Dyskeratosis Congenit Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study.

Leukemia Clinical Trial using Eltrombopag

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML).
Eltrombopag

Hepatitis C Infection, or Thrombocytopenia Clinical Trial using romiplostim; ribavirin; placebo; PEG-interferon alfa-2a; laboratory biomarker analysis

University of Southern California - Recruiting 18 years or older.
- A Double-Blind, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who Are Not Candidates for Antiviral Treatment With Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia.
romiplostim; ribavirin; placebo; PEG-interferon alfa-2a; laboratory biomarker analysis

Isolated Chemotherapy-induced Thrombocytopenia Clinical Trial using romiplostim,; Control cohort

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Randomized Open Label Phase II Study of Romiplostim Versus Observation for Chemotherapy Induced Thrombocytopenia.
romiplostim,; Control cohort

Immune Thrombocytopenia Purpura Clinical Trial using MK-8723; Matching Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Two-Part, Single Rising Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MK-8723 in Healthy Adults and Patients With Immune Thrombocytopenia Purpura.
MK-8723; Matching Placebo

Thrombocytopenia Associated With Liver Disease Clinical Trial using avatrombopag (lower baseline platelet count); placebo (lower baseline platlet count); avatrombopag (higher baseline platelet count); placebo (higher baseline platelet count)

Eisai Inc. - Recruiting 18 years or older.
- A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure.
avatrombopag (lower baseline platelet count); placebo (lower baseline platlet count); avatrombopag (higher baseline platelet count); placebo (higher baseline platelet count)

Thrombocytopenia Clinical Trial using avatrombopag

Eisai Inc. - Recruiting 20 years to 55 years.
- .
avatrombopag

Anemia, Hematopoietic/Lymphoid Cancer, Lymphopenia, Neutropenia, Clinical Trial using Allogeneic hematopoietic stem cell transplantation; Peripheral blood stem cell transplantation; Management of therapy complications

Thomas Jefferson University - Recruiting 18 years or older.
- Compassionate Use of the CliniMACSr CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells.
Allogeneic hematopoietic stem cell transplantation; Peripheral blood stem cell transplantation; Management of therapy complications

Thrombocytopenia Clinical Trial using Eltrombopag; Placebo

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Eltrombopag for Post Transplant Thrombocytopenia.
Eltrombopag; Placebo

CLL, or Leukemia Clinical Trial using Eltrombopag

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia.
Eltrombopag

Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II M Clinical Trial using romiplostim

New York University School of Medicine - Recruiting 18 years or older.
- Phase II Trial Evaluating the Efficacy and Safety of Romiplostim (Nplate) Treatment of Chemotherapy Induced Thrombocytopenia in Patients With Multiple Myeloma.
romiplostim

Anemia, Hematologic Neoplasm, Neutropenia, Pancytopenia, or Throm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Screening Protocol for Subjects Being Evaluated for Hematology Branch Protocols.

Thrombotic Thrombocytopenia Purpura, or TTP Clinical Trial using N-Acetylcysteine

Puget Sound Blood Center - Recruiting 18 years or older.
- A Pilot Study of N-acetylcysteine in Suspected Thrombotic Thrombocytopenia Purpura.
N-Acetylcysteine

Primary Thrombocytopenia Clinical Trial using NewGam 10%

Octapharma - Recruiting 18 years to 80 years.
- Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia.
NewGam 10%

Medical Patient, or Thrombocytopenia Clinical Trial using Fondaparinux

G. d'Annunzio University - Recruiting 18 years or older.
- Thromboprophylaxis With Fondaparinux of Deep Vein Thrombosis and Pulmonary Embolism in the Acutely-ill Medical Inpatients With Thrombocytopenia.
Fondaparinux

Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopeni Clinical Trial using Eltrombopag Olamine

Fondazione Progetto Ematologia - Recruiting 18 years or older.
- Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs).
Eltrombopag Olamine

Purpura, Thrombocytopenic, Idiopathic, or Autoimmune Thrombocytop Clinical Trial

Henri Mondor University Hospital - Recruiting 18 years or older.
- The ITP-RITUX Cohort: An Observational Study on Rituximab Off-label Use for Immune ThrombocytoPenia..

Purpura, Thrombocytopenic, Idiopathic Clinical Trial using Conventional-dose prednisone group; High-dose dexamethasone group

Shandong University - Recruiting 18 years to 80 years.
- High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial.
Conventional-dose prednisone group; High-dose dexamethasone group

Heparin-Induced Thrombocytopenia, or Thrombosis Clinical Trial

Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older.
- Generation of HIT-antibodies Without Prior Heparin Exposure Following Orthopedic Surgery (Subgroup Study) (Change of Coagulation Parameters Under Exposition With New Anticoagulants [Title of the Main Study]).